Pharma BD Deal Intelligence
A quiet bolt-on that compounded steadily: Zoetis's $765M acquisition of Norway's PHARMAQ made it the global leader in fish/aquaculture vaccines, with fish-species revenue growing roughly 3x from $80M in 2014 to $242M by 2024, though the deal sits at the margins of core pharma classification.
Bloomberg framed the acquisition as Zoetis pivoting into one of animal health's highest-growth segments, leveraging PHARMAQ's category leadership in Norwegian…
Fierce Pharma reported Zoetis shareholders 'applauded' the $765M PHARMAQ deal — shares rose >5% the day of announcement on the combination of strong…
TheStreet flagged the deal as accretive long-term but neutral to 2016 adjusted earnings, with aquaculture serving as a secular protein-demand growth thesis…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Zoetis agreed to acquire Norway-based PHARMAQ, the global leader in aquaculture health, from Permira-led investors for approximately $765M, expanding Zoetis into fish health and vaccines. Borderline by pharma vs. animal health classification — included as platform-level vaccine deal.
Assessment window: 5yr post-close.
$80M PHARMAQ revenue 2014 (acquisition reference baseline)
Aquaculture is the fastest-growing animal-protein production segment globally, with farmed fish vulnerable to bacterial, viral, and parasitic diseases (furunculosis, IPN, PD, sea lice) that cause ~10% mortality and >$10B in annual losses worldwide. Salmon farming concentrates in Norway, Chile, Scotland, and Canada. Vaccines are the primary preventive intervention, offering meaningful welfare and yield economics versus parasiticide-only protocols.
Pre-deal, the aquaculture animal-health space was fragmented across MSD Animal Health (Aquavac, the Slice sea-lice parasiticide), Elanco/Novartis Animal Health (which Lilly later spun out), Virbac, and PHARMAQ as the standalone leader in salmon vaccines. PHARMAQ held the dominant position in Norwegian and Chilean salmon vaccine sales — including Alpha Ject multivalent vaccines and Slice (emamectin benzoate) for sea lice. Zoetis pre-acquisition had limited fish-health presence, focusing on companion animals and livestock. The $765M acquisition gave Zoetis the global #1 platform in the fastest-growing animal-health vertical (~10% CAGR per Zoetis disclosure), with PHARMAQ's $80M 2014 revenue base implying a ~9.5x revenue multiple — premium pricing justified by category leadership and scarcity of comparable assets. Fierce Pharma reported Zoetis shares rose >5% on announcement day and the company guided the deal as neutral to 2016 adjusted EPS and accretive thereafter. The deal repositioned Zoetis from a pure terrestrial animal-health pure-play into a diversified protein-production health franchise, anticipating aquaculture's secular rise as a global protein source. Sources: https://investor.zoetis.com/news/news-details/2015/Zoetis-to-Acquire-PHARMAQ-the-Global-Leader-in-Vaccines-and-Innovation-for-Health-Products-in-Aquaculture/default.aspx ; https://www.fiercepharma.com/m-a/zoetis-shareholders-applaud-765m-pharmaq-buy-and-strong-earnings
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Zoetis Inc. / PHARMAQ Holding AS (this deal) | 2015 | $765M | 82 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2015 deals · Other deals